JP6846352B2 - キメラ抗原受容体 - Google Patents

キメラ抗原受容体 Download PDF

Info

Publication number
JP6846352B2
JP6846352B2 JP2017541919A JP2017541919A JP6846352B2 JP 6846352 B2 JP6846352 B2 JP 6846352B2 JP 2017541919 A JP2017541919 A JP 2017541919A JP 2017541919 A JP2017541919 A JP 2017541919A JP 6846352 B2 JP6846352 B2 JP 6846352B2
Authority
JP
Japan
Prior art keywords
cells
car
domain
seq
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509893A (ja
Inventor
真哉 田中
真哉 田中
平野　直人
直人 平野
勇紀 籠谷
勇紀 籠谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Bio Inc
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Publication of JP2018509893A publication Critical patent/JP2018509893A/ja
Application granted granted Critical
Publication of JP6846352B2 publication Critical patent/JP6846352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
JP2017541919A 2015-02-12 2016-02-11 キメラ抗原受容体 Active JP6846352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115527P 2015-02-12 2015-02-12
US62/115,527 2015-02-12
PCT/CA2016/050126 WO2016127257A1 (en) 2015-02-12 2016-02-11 Chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020186004A Division JP2021036883A (ja) 2015-02-12 2020-11-06 キメラ抗原受容体

Publications (2)

Publication Number Publication Date
JP2018509893A JP2018509893A (ja) 2018-04-12
JP6846352B2 true JP6846352B2 (ja) 2021-03-24

Family

ID=56614021

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017541919A Active JP6846352B2 (ja) 2015-02-12 2016-02-11 キメラ抗原受容体
JP2020186004A Pending JP2021036883A (ja) 2015-02-12 2020-11-06 キメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020186004A Pending JP2021036883A (ja) 2015-02-12 2020-11-06 キメラ抗原受容体

Country Status (7)

Country Link
US (2) US10336810B2 (https=)
EP (1) EP3256496B1 (https=)
JP (2) JP6846352B2 (https=)
KR (1) KR102607152B1 (https=)
CA (1) CA2974998C (https=)
ES (1) ES2857998T3 (https=)
WO (1) WO2016127257A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857998T3 (es) 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB201518816D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Receptor
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
NZ750256A (en) 2016-08-03 2026-02-27 Dipersio John F Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP7206214B2 (ja) * 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
CA3098014A1 (en) * 2018-04-27 2019-10-31 Crispr Therapeutics Ag Anti-bcma car-t-cells for plasma cell depletion
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020050667A1 (ko) * 2018-09-05 2020-03-12 공석경 고형암을 위한 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
KR20210132668A (ko) * 2019-02-21 2021-11-04 아르벨 리미티드 인공 면역감시 키메라 항원 수용체(ai-car) 및 이를 발현하는 세포
EP3931208A1 (en) 2019-03-01 2022-01-05 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
BR112021017365A2 (pt) 2019-03-01 2022-02-01 Allogene Therapeutics Inc Receptores de citocina quiméricos constitutivamente ativos
GB201911187D0 (en) * 2019-08-05 2019-09-18 Autolus Ltd Receptor
GB201912515D0 (en) * 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
WO2021041806A1 (en) 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
CN114761424B (zh) * 2019-09-05 2025-09-19 波赛达治疗公司 同种异体细胞组合物和使用方法
CN110717956B (zh) * 2019-09-30 2023-06-20 重庆大学 一种有限角投影超像素引导的l0范数最优化重建方法
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CA3166420A1 (en) * 2020-01-14 2021-07-22 Synthekine, Inc. Il2 orthologs and methods of use
CN115038453A (zh) * 2020-01-14 2022-09-09 辛德凯因股份有限公司 具有改变的icd stat信号转导的cd122
JP2023514407A (ja) 2020-02-24 2023-04-05 アロジーン セラピューティクス，インコーポレイテッド 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞
CN115427440A (zh) * 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体
WO2021183795A1 (en) * 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
KR20230011948A (ko) * 2020-04-17 2023-01-25 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 향상된 기능을 갖는 면역 세포
EP4139345A1 (en) * 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4261225A4 (en) 2020-12-10 2024-11-13 Eutilex Co., Ltd. ANTI-PD-1 ANTIBODY AND ITS USES
CN114716548B (zh) 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN113512125B (zh) * 2021-04-26 2024-01-19 北京双赢科创生物科技有限公司 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞
WO2023044457A1 (en) 2021-09-17 2023-03-23 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
WO2023159000A2 (en) * 2022-02-15 2023-08-24 Memorial Sloan-Kettering Cancer Center Compositions including cytotoxic innate lymphoid cells and uses therof
WO2023158997A2 (en) * 2022-02-15 2023-08-24 Memorial Sloan-Kettering Cancer Center Compositions including killer innate-like t cells and uses therof
US20250319131A1 (en) * 2022-07-11 2025-10-16 The Board Of Trustees Of The Leland Stanford Junior University Tunable cytokine receptor signaling domains
IL318546A (en) 2022-07-26 2025-03-01 Aimed Bio Inc Anti-ROR1 antibody and its uses
EP4342907A1 (en) 2022-09-21 2024-03-27 AvenCell Europe GmbH Switchable chimeric antigen receptors and their use
EP4593871A1 (en) 2022-09-30 2025-08-06 Caribou Biosciences, Inc. Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
EP4633648A1 (en) * 2022-12-15 2025-10-22 Carisma Therapeutics Inc. Chimeric antigen receptors including jak/stat binding domains and modified immune cells
WO2025096673A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising cells targeting cancer and methods of using the same
WO2026006794A1 (en) * 2024-06-27 2026-01-02 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptors and uses thereof
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US6077947A (en) 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US9746470B2 (en) 2011-05-09 2017-08-29 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2014268364A1 (en) * 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
ES2857998T3 (es) 2015-02-12 2021-09-29 Univ Health Network Receptores de antígenos quiméricos

Also Published As

Publication number Publication date
US10822392B2 (en) 2020-11-03
KR102607152B1 (ko) 2023-11-27
US10336810B2 (en) 2019-07-02
CA2974998A1 (en) 2016-08-18
US20190359685A1 (en) 2019-11-28
CA2974998C (en) 2022-04-26
WO2016127257A1 (en) 2016-08-18
JP2021036883A (ja) 2021-03-11
EP3256496A1 (en) 2017-12-20
US20180037630A1 (en) 2018-02-08
EP3256496A4 (en) 2018-12-12
KR20170116084A (ko) 2017-10-18
ES2857998T3 (es) 2021-09-29
JP2018509893A (ja) 2018-04-12
EP3256496B1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
JP6846352B2 (ja) キメラ抗原受容体
US20260055157A1 (en) Methods of making chimeric antigen receptor-expressing cells
AU2024227744A1 (en) Methods of making chimeric antigen receptor-expressing cells
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
JP2023002556A (ja) 固形腫瘍を治療するためのキメラ抗原受容体細胞
KR20220124173A (ko) Lilrb1-기반 키메라 항원 수용체
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
CN110511912B (zh) 免疫细胞的功能调节
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
US20230192848A1 (en) Engineered cell compositions and methods of use thereof
CN110257338A (zh) 嵌合细胞因子受体
TW202026006A (zh) 使用融合蛋白進行tcr再程式化之組成物及方法
WO2022232277A1 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH
KR20250046298A (ko) 자연 살해 세포 기능을 향상시키기 위한 표적 유전자의 유전자 편집
US20240131068A1 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
US11701385B2 (en) Modulation of cell function for immunotherapy
US20260014199A1 (en) Modified immune cells
US20240269182A1 (en) Modified Chimeric Antigen Receptor and Use thereof
KR20240034205A (ko) 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터
US12043654B2 (en) Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN116732068A (zh) 一种编码嵌合抗原受体的基因及其载体、修饰细胞和应用
TW202216752A (zh) 用於過繼細胞療法之提供靶向共刺激之嵌合分子
JP2022001021A (ja) Ｃｄ２６特異的キメラ抗原受容体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201106

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201207

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210301

R150 Certificate of patent or registration of utility model

Ref document number: 6846352

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250